Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Subscribe To Our Newsletter & Stay Updated